Economic burden of Parkinson's disease in a developing country: A retrospective cost analysis in Shanghai, China

Movement Disorders

Volumn 21, Issue 9, 2006, Pages 1439-1443

  Wang, Gang ^a   Cheng, Qi ^a   Zheng, Rhui ^a   Tan, Yu Yan ^a   Sun, Xiao Kang ^a   Zhou, Hai Yan ^a   Ye, Xiao Lai ^a   Wang, Ying ^a   Wang, Zeng ^a   Sun, Bo Min ^b   Chen, Sheng Di ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Costs; Hoehn Yahr stage; Parkinson's disease; Resource use

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIHYDROERGOCRYPTINE; ENTACAPONE; LEVODOPA; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; ROPINIROLE; SELEGILINE;

ADULT; AGED; ARTICLE; CHINA; CHINESE MEDICINE; CONTROLLED STUDY; CORRELATION ANALYSIS; COST BENEFIT ANALYSIS; COST OF ILLNESS; DEVELOPING COUNTRY; DIET THERAPY; DISEASE SEVERITY; DOSE CALCULATION; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; INCOME; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; OUTPATIENT CARE; PARKINSON DISEASE; PRIORITY JOURNAL; PRODUCTIVITY; RETROSPECTIVE STUDY; SOCIOECONOMICS;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTIPARKINSON AGENTS; CHINA; COMBINED MODALITY THERAPY; COST OF ILLNESS; COSTS AND COST ANALYSIS; DELIVERY OF HEALTH CARE; DEVELOPING COUNTRIES; FEMALE; HEALTH CARE COSTS; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PATIENT ADMISSION; PATIENT CARE TEAM; POPULATION DYNAMICS; RETROSPECTIVE STUDIES;

EID: 33750321921     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20999     Document Type: Article

References (23)

1. Scheife RT, Schumock GT, Burstein A, Gottwald MD, Luer MS. Impact of Parkinson's disease and its pharmacological treatment on quality of life and economic outcomes. Am J Health Syst Pharm 2000;57:953-962.
2. Whetten-Goldstein K, Sloan F, Kulas E, Cutson T, Schenkman M. The burden of Parkinson's disease on society, family and the individual. J Am Geriatr Soc 1997;45:844-849.
3. Singer E. Social costs of Parkinson's disease. J Chronic Dis 1973; 26:243-254.
4. Rubenstein LM, Chrischilles EA, Voelker MD. The impact of Parkinson's disease on health status, health expenditures, and productivity. Pharmacoeconomics 1997;12:486-498.
5. Dodel RC, Singer M, Kohne-Volland R, et al. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998;14:299-312.
6. Cubo E, Alvarez E, Morant C, et al. Burden of disease related to Parkinson's disease in Spain in the year 2000. Mov Disord 2005; 20:1481-1487.
7. Zhang ZX, Roman GC, Hong Z, et al. Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet 2005; 365:595-597.
8. Bureau of Shanghai Statistics, 2004 year statistics almanac of Shanghai. Available at: http://www.stats-sh.gov.cn/2004shtj/tjnj/tjnj2005.htm. Accessed May 2005.
9. Minguez-Castellanos A, Escamilla-Sevilla F, Katati MJ, et al. Different patterns of medication change after subthalamic or pallidal stimulation for Parkinson's disease: target related effect or selection bias? J Neurol Neurosurg Psychiatry 2005;76:34-39.
10. Gupta M, Singh G, Khwaja GA, Mehndiratta MM. Hallucinations in Parkinson's disease-a study of forty three patients. J Assoc Physicians India 2004;52:703-706.
11. Junghanns S, Glockler T, Reichmann H. Switching and combining of dopamine agonists. J Neurol 2004;251(Suppl. 6):VI19-V123.
12. Hobson DE, Lang AE, Martin WR, et al. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey. JAMA 2002;287:455-463.
13. Poewe W. Should treatment of Parkinson's disease be started with a dopamine agonist? Neurology 1998;51:S21-S24.
14. Hagell P, Nordling S, Reimer J, Grabowski M, Persson U. Resource use and costs in a Swedish cohort of patients with Parkinson's disease. Mov Disord 2002;17:1213-1220.
15. Findley L, Aujla M, Bain PG, et al. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Mov Disord 2003;18:1139-1145.
16. Jost WH. Costs in the treatment of parkinsonism. J Neurol 2000; 247:(Suppl. 4)IV/31-IV/33.
17. Muller T, Voss B, Hellwig K, Josef Stein F, Schulte T, Przuntek H. Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic. CNS Drugs 2004; 18:105-111.
18. Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G. Burden of illness in Parkinson's disease. Mov Disord 2005;20:1449-1454.
19. Spottke AE, Reuter M, Machat O, et al. Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics 2005;23:817-836.
20. Lindgren P. Economic evidence in Parkinson's disease: a review. Eur J Health Econ 2004;5:(Suppl. 1)S63-S66.
21. National Bureau of Statistics of China. 2004 year statistics almanac of China. Available at: http://www.stats.gov.cn/tjsj/ndsj/yb2004-c/ indexch.htm. Accessed May 2005.
22. Statistics Sweden. Financial accounts, annual. Available at: http://www.scb.se/templatesttableOrChart_28872.asp. Accessed May 2005.
23. U.S. Census Bureau. Income, Poverty, and Health Insurance Coverage in the United States: 2004 (P60-229). Available at: http://www.census.gov/ prod/2005pubs/P60-229.pdf. Accessed May 2005.